Back to News
Market Impact: 0.4
BioCryst Wins FDA Approval For Orladeyo Oral Pellets In HAE Patients Aged 12 And Older
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
The FDA approved BioCryst Pharmaceuticals’ oral pellet formulation of Orladeyo to prevent hereditary angioedema attacks in people aged 12 and older. The article provides no financial figures or reported share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
BCRX0.75
More News
- New Mexico took on Meta alone and won a $25 billion judgment over Facebook’s privacy violations
- Meta ordered to pay $25 billion in case related to Cambridge Analytica scandal
- Judge orders Meta to pay $25bn in fines for Facebook privacy violations
- Meta ordered to pay $25 billion penalty in New Mexico Cambridge Analytica case
- Meta ordered to pay $25 billion in penalties over the Cambridge Analytica scandal
- Sovereign wealth funds' China and Hong Kong investments surge 190% after a bruising slump